Slide background

European Musculo-Skeletal Oncology Society E.M.S.O.S.


Clear cell chondrosarcoma

Clear cell chondrosarcoma is a rare variant of chondrosarcoma, behaving as a low grade malignant bone tumor and characterized by a proliferation of tumor cells with clear cytoplasm.

Clear cell chondrosarcomas account for around 2% of all chondrosarcomas. They have been described in most bones of the body but usually affect the proximal epiphysis of the humerus or femur.

Doz. Dimosthenis Andreou, Münster, Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.


Downloads
pdfClear cell chondrosarcoma EMSOS study protocol.pdf361.27 KB
xlsClear cell chondrosarcoma EMSOS study protocol.xls36.00 KB

Tenosynovial giant cell tumour

Diffuse and nodular type Tenosynovial Giant Cell Tumour (TGCT), previously named Pigmented Villonodular Synovitis (PVNS), is a rare, locally aggressive, non-metastasizing neoplasm. Current literature primarily consists of several small cohorts containing relatively inhomogeneous data. Systematic-/meta-analysis at present are only describing or pooling their results. In order to predict outcome; individual data in one large cohort, containing important characteristics; e.g. frequency of local recurrence, extent or disease severity (nodular versus diffuse), influence of surgical technique (arthroscopic versus open synovectomy), primary treatment after referral, etc. is therefore essential.

Your help in gathering (un)published data and compile a global TGCT retrospective database, to help us evaluate this orphan disease, is much appreciated.

Monique Mastboom: This email address is being protected from spambots. You need JavaScript enabled to view it.


Downloads
xlsTGCT global database EMSOSdef.xls524 KB
pdfTGCT global database EMSOS case inclusion protocol def.pdf496.3 KB
pdfHow to complete TGCT database def.pdf426.66 KB

Mazabraud syndrome

Mazabraud Syndrome is a very rare combination of fibrous dysplasia (FD) and intramusculary myxomas. Both entities are caused by activating GNAS-mutations and while FD is often diagnosed at a younger age, myxomas tend to arise later, often in the fourth or fifth decade of life, and are localized adjacent to FD lesions in the majority of the patients. The myxomas can lead to mechanical problems and symptoms of pain. Excision of the myxomas has been proposed, although outcome of surgical interventions and whether there are predictive factors for recurrence of the myxomas remains eluded.

If you need any assistance please contact Bas Majoor,  This email address is being protected from spambots. You need JavaScript enabled to view it.

 

   Case inclusion protocol EMSOS study Mazabraud Syndrome pds.docx14.93 KB
  Mazabraud database multicentre file pds.xls48 KB

 

EMSOS Study "Angiosarcom"

Angiosarcoma is the malignant end of the spectrum of vascular tumors, spanning diagnosis including hemangiomas, hemangioendothelioma, well-differentiated and poorly-differentiated angiosarcoma.

Angiosarcoma of bone is rare, accounting for <1% of all primary bone sarcomas and it is associated with a poor prognosis. Although any age can be affected, the incidence is highest between 50 and 70 years of age.

Angiosarcoma of bone may present as unifocal or multifocal disease. The most common locations of unifocal tumor are the long and short tubular bones, followed by the pelvis, and trunk.

Histologically, angiosarcomas of bone are composed of anastomosing vascular channels lined by atypical endothelial cells with enlarged nuclei, prominent nucleoli, and increased mitoses. Inflammatory cells, mostly eosinophils, may be present.

Given the rarity of angiosarcoma of bone, the literature is limited regarding treatment and outcome of patients with this tumor.

The role of chemotherapy and prognostic factors for these patients remain unclear.

Under the auspices of the EMSOS, a retrospective  study has been launched with the aim of  improving  our knowledge on the natural history of the tumor and on prognostic and predictive factors of survival.

Stefano Ferrari MD
SSD Chemioterapia dei Tumori Muscoloscheletrici
Istituto Ortopedico Rizzoli – WWW.ior.it
Via Pupilli 1, 40136 Bologna. Italy
This email address is being protected from spambots. You need JavaScript enabled to view it.

Bone Angiosarcoma-Legend for Spreadsheet.pdf43.27 KB
Angiosarcoma of Bone Spreadsheet July 2015.xls41 KB

 

EMSOS Study "Adamantinoma"

 Case inclusion protocol EMSOS study Adamantinoma.pdf26.59 KB

 Adamantinoma database multicentre file.xls 51.5 KB

 

Michiel van de Sande
Leiden, The Netherlands
This email address is being protected from spambots. You need JavaScript enabled to view it. 

DGOOC / EMSOS study "Clear cell sarcoma"

Osteosarcoma after retinoblastoma

Contact Sebastian Asaftei, Torino / This email address is being protected from spambots. You need JavaScript enabled to view it.

European Relapsed Osteosarcoma Registry "EURELOS"

EURELOS EUropean RELapsed OsteoSarcoma Registry